French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

    NEXT STORY
    Helix BioPharma Corp. Closes $3.0 Million Private Placement
    PREV STORY
    Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

    MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. ...

    author_avatar
    NASDAQ Market News

    NanoVibronix Provides Business Update for the Second Quarter of 2018

    Revenue increases 153% for the second quarter of 2018 ELMSFORD, N.Y., Aug. 16, 2018 ...

    author_avatar
    NASDAQ Market News

    Global Medical Device Connectivity Market Is Expected to Reach USD 8.76 Billion by 2027 : Fior Markets

    author_avatar
    NASDAQ Market News